Tidligere behandlede patienter I studie CAL30001 blev 182 tidligere behandlede patienter med virologisk svigt randomiseret og de modtag enten Kivexa én gang daglig eller abacavir 300 mg to gange daglig plus lamivudin 300 mg én gang daglig, begge i kombination med tenofovir og en PI eller en NNRTI i 48 uger.
Therapy-experienced patients In study CAL30001, 182 treatment-experienced patients with virologic failure were randomised and received treatment with either Kivexa once daily or abacavir 300 mg twice daily plus lamivudine 300 mg once daily, both in combination with tenofovir and a PI or an NNRTI for 48 weeks.